Results 1 to 10 of about 365,877 (337)
Gli1 mediates lung cancer cell proliferation and sonic hedgehog-dependent mesenchymal cell activation. [PDF]
, 2013 Non-Small-Cell-Lung-Cancer (NSCLC) represents approximately 85% of all lung cancers and remains poorly understood. While signaling pathways operative during organ development, including Sonic Hedgehog (Shh) and associated Gli transcription factors (Gli1 ...
Bermudez, Olga +4 more
core +16 more sources
Фармакоэкономика, 2023 Objective: to evaluate the clinical and economic effectiveness of alectinib in comparison with lorlatinib in adult patients with advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).Materials and methods. The calculations
A. S. Kolbin +3 more
doaj +1 more source
Effect of using different co-ligands during 99mTc-labeling of J18 peptide on SK-MES-1 cell binding and tumor targeting [PDF]
Iranian Journal of Basic Medical Sciences, 2021 Objective(s): Lung cancer is the main cause of cancer death, and its incidence is increasing worldwide. The goal of this study is to evaluate in vitro and in vivo tumor targeting behavior of [99mTc]Tc -HYNIC-(Ser)3-J18 in lung carcinoma (SK-MES-1 ...
Seyed Jalal Hosseinimehr +3 more
doaj +1 more source
Сибирский онкологический журнал, 2023 Aim of the study: to evaluate prognostic value of baseline lung immune prognostic index (LIPI) and its modification (mLIPI) for metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI).Material and methods ...
D. I. Yudin +4 more
doaj +1 more source
Cancer Cell International, 2020 Background Our previous clinical study has shown that Chinese herbal medicine (CHM) Fuzheng Kang-Ai (FZKA) decoction is effective in treating advanced lung cancer patients through prolonging the drug resistance to Gefitinib (GFTN).
Sumei Wang +5 more
doaj +1 more source
OncoImmunology, 2021 Immune checkpoint inhibitors (ICIs) have improved the survival of patients with non-small cell lung cancer (NSCLC) by reinvigorating tumor-specific T cell responses.
Fiamma Berner +30 more
doaj +1 more source
South Asian Journal of Cancer, 2022 Akhil Kapoor Introduction The prognosis of anaplastic lymphoma kinase (ALK) fusion-positive metastatic non-small cell lung cancer (mNSCLC) patients has improved drastically since the introduction of targeted
Satvik Khaddar +9 more
doaj +1 more source
OncoImmunology, 2021 Somatic mutations of STK11 or KEAP1 are associated with poor clinical outcomes for advanced non-small-cell lung cancer (aNSCLC) patients receiving immune checkpoint inhibitors (ICIs), chemotherapy, or targeted therapy.
Wei Nie +19 more
doaj +1 more source
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Drugs in Context, 2022 Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common KRAS ...
Biagio Ricciuti +10 more
doaj +1 more source
Open Medicine, 2023 The efficacy of immune checkpoint inhibitors (ICIs) on KRAS-mutant advanced non-small cell lung cancer (NSCLC) remains controversial. This retrospective study compared the effects of ICIs treatment and chemotherapy on the prognosis of patients with KRAS ...
Gu Xiaodong +10 more
doaj +1 more source